ARAY
Price
$2.18
Change
-$0.02 (-0.91%)
Updated
Apr 25, 6:59 PM EST
5 days until earnings call
CERS
Price
$1.70
Change
+$0.04 (+2.41%)
Updated
Apr 25, 6:59 PM EST
6 days until earnings call
Ad is loading...

Analysis and predictions ARAY vs CERS

Header iconARAY vs CERS Comparison
Open Charts ARAY vs CERSBanner chart's image
Accuray
Price$2.18
Change-$0.02 (-0.91%)
Volume$223.32K
CapitalizationN/A
Cerus
Price$1.70
Change+$0.04 (+2.41%)
Volume$482.9K
CapitalizationN/A
View a ticker or compare two or three
ARAY vs CERS Comparison Chart

Loading...

ARAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CERSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ARAY vs. CERS commentary
Apr 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARAY is a Hold and CERS is a Hold.

COMPARISON
Comparison
Apr 26, 2024
Stock price -- (ARAY: $2.18 vs. CERS: $1.70)
Brand notoriety: ARAY and CERS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ARAY: 79% vs. CERS: 57%
Market capitalization -- ARAY: $244.95M vs. CERS: $342.62M
ARAY [@Medical Specialties] is valued at $244.95M. CERS’s [@Medical Specialties] market capitalization is $342.62M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARAY’s FA Score shows that 0 FA rating(s) are green whileCERS’s FA Score has 0 green FA rating(s).

  • ARAY’s FA Score: 0 green, 5 red.
  • CERS’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than ARAY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARAY’s TA Score shows that 4 TA indicator(s) are bullish while CERS’s TA Score has 4 bullish TA indicator(s).

  • ARAY’s TA Score: 4 bullish, 3 bearish.
  • CERS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both ARAY and CERS are a good buy in the short-term.

Price Growth

ARAY (@Medical Specialties) experienced а -1.36% price change this week, while CERS (@Medical Specialties) price change was +3.66% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.50%. For the same industry, the average monthly price growth was -2.77%, and the average quarterly price growth was +17.17%.

Reported Earning Dates

ARAY is expected to report earnings on Aug 15, 2024.

CERS is expected to report earnings on Aug 01, 2024.

Industries' Descriptions

@Medical Specialties (+0.50% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for ARAY with price predictions.
OPEN
A.I.dvisor published
a Summary for CERS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than ARAY($245M). CERS YTD gains are higher at: -21.296 vs. ARAY (-22.968). ARAY has higher annual earnings (EBITDA): 5.93M vs. CERS (-26.34M). ARAY has more cash in the bank: 72.8M vs. CERS (65.9M). CERS has less debt than ARAY: CERS (96M) vs ARAY (202M). ARAY has higher revenues than CERS: ARAY (447M) vs CERS (156M).
ARAYCERSARAY / CERS
Capitalization245M343M71%
EBITDA5.93M-26.34M-23%
Gain YTD-22.968-21.296108%
P/E RatioN/AN/A-
Revenue447M156M287%
Total Cash72.8M65.9M110%
Total Debt202M96M210%
FUNDAMENTALS RATINGS
ARAY vs CERS: Fundamental Ratings
ARAY
CERS
OUTLOOK RATING
1..100
689
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
8057
P/E GROWTH RATING
1..100
51100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (50) in the Medical Specialties industry is somewhat better than the same rating for ARAY (83). This means that CERS’s stock grew somewhat faster than ARAY’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ARAY (100). This means that CERS’s stock grew similarly to ARAY’s over the last 12 months.

ARAY's SMR Rating (96) in the Medical Specialties industry is in the same range as CERS (97). This means that ARAY’s stock grew similarly to CERS’s over the last 12 months.

CERS's Price Growth Rating (57) in the Medical Specialties industry is in the same range as ARAY (80). This means that CERS’s stock grew similarly to ARAY’s over the last 12 months.

ARAY's P/E Growth Rating (51) in the Medical Specialties industry is somewhat better than the same rating for CERS (100). This means that ARAY’s stock grew somewhat faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARAYCERS
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
70%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
ARAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CERSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NQCFX24.92N/A
N/A
NorthQuest Capital
DRTHX17.72-0.04
-0.23%
BNY Mellon Sustainable US Eq Fd Z
PRZIX33.56-0.10
-0.30%
T. Rowe Price Emerging Markets Stock I
MXMSX10.76-0.06
-0.55%
Empower Small Cap Growth Instl
GSSSX36.11-0.27
-0.74%
Goldman Sachs Small Cap Value Svc

ARAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARAY has been loosely correlated with VREX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAY jumps, then VREX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARAY
1D Price
Change %
ARAY100%
-0.91%
VREX - ARAY
43%
Loosely correlated
-1.05%
VCYT - ARAY
42%
Loosely correlated
-2.11%
KIDS - ARAY
41%
Loosely correlated
-4.04%
TWST - ARAY
41%
Loosely correlated
+1.07%
CERS - ARAY
41%
Loosely correlated
+2.41%
More

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+2.41%
VCYT - CERS
52%
Loosely correlated
-2.11%
TWST - CERS
49%
Loosely correlated
+1.07%
KIDS - CERS
46%
Loosely correlated
-4.04%
CDNA - CERS
45%
Loosely correlated
-5.26%
TFX - CERS
43%
Loosely correlated
-2.11%
More